In agreement with this hypothesis, we found PIK3CA and pan-c-erb inhibitors to be highly synergistic, well-tolerated in vivo in animals and able to prevent development of resistance in all preclinical endometrial cancer model so far tested (Lopez et al., 2014, Lopez et al., 2015). Here, PIK3CA is linked to endometrial cancer.